159 related articles for article (PubMed ID: 37271278)
1. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Nomura T; Shibahara T; Uchiyama T; Yamamoto N; Shibui T; Yakushiji T; Watanabe A; Muramatsu K; Ogane S; Murayama M; Sekine R; Nakata E; Fujimoto Y
Bull Tokyo Dent Coll; 2013; 54(2):117-25. PubMed ID: 23903583
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database.
de Boissieu P; Gaboriau L; Morel A; Trenque T
Fundam Clin Pharmacol; 2016 Oct; 30(5):450-8. PubMed ID: 27315575
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
Di Fede O; Fusco V; Matranga D; Solazzo L; Gabriele M; Gaeta GM; Favia G; Sprini D; Peluso F; Colella G; Vescovi P; Campisi G
Eur J Intern Med; 2013 Dec; 24(8):784-90. PubMed ID: 23768563
[TBL] [Abstract][Full Text] [Related]
5. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
7. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia.
Hong JW; Nam W; Cha IH; Chung SW; Choi HS; Kim KM; Kim KJ; Rhee Y; Lim SK
Osteoporos Int; 2010 May; 21(5):847-53. PubMed ID: 19633881
[TBL] [Abstract][Full Text] [Related]
8. Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: A systematic review.
Martins LHI; Ferreira DC; Silva MT; Motta RHL; Franquez RT; Bergamaschi CC
Oral Dis; 2023 Jan; 29(1):75-99. PubMed ID: 34402147
[TBL] [Abstract][Full Text] [Related]
9. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
López-Cedrún JL; Sanromán JF; García A; Peñarrocha M; Feijoo JF; Limeres J; Diz P
Br J Oral Maxillofac Surg; 2013 Dec; 51(8):874-9. PubMed ID: 23866309
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
Rugani P; Luschin G; Jakse N; Kirnbauer B; Lang U; Acham S
Clin Oral Investig; 2014; 18(2):401-7. PubMed ID: 23749244
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
O'Ryan FS; Lo JC
J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Hoefert CS; Albert M; Munz A; Grimm M; Northoff H; Reinert S; Alexander D
Clin Oral Investig; 2015 Jul; 19(6):1307-18. PubMed ID: 25411080
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases.
Pelaz A; Junquera L; Gallego L; García-Consuegra L; García-Martínez L; Cutilli T; Olay S
Acta Otorrinolaringol Esp; 2015; 66(3):139-47. PubMed ID: 25308796
[TBL] [Abstract][Full Text] [Related]
14. Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Sade Hoefert C; Munz A; Northoff H; Yuan A; Reichenmiller K; Reinert S; Grimm M
Clin Oral Investig; 2016 Jun; 20(5):1043-54. PubMed ID: 26349768
[TBL] [Abstract][Full Text] [Related]
15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
Katz J; Ordoveza PA
Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
[TBL] [Abstract][Full Text] [Related]
17. Awareness and Attitude among Physicians Regarding Bisphosphonaterelated Osteonecrosis of the Jaw (BRONJ): A Cross-sectional Study.
Priyadarshini V; Ramachandra SS; Ganganna A
Curr Drug Saf; 2023; 18(3):361-367. PubMed ID: 35570536
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors associated to Medication-Related Osteo Necrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.
Cuozzo A; Iorio-Siciliano V; Vaia E; Mauriello L; Blasi A; Ramaglia L
J Stomatol Oral Maxillofac Surg; 2022 Nov; 123(6):616-621. PubMed ID: 35609780
[TBL] [Abstract][Full Text] [Related]
19. [The rare case of osteonecrosis of the jaws in a patient treated with bisphosphonates for osteoporosis].
Lewandowski B; Brodowski R; Kość T; Migut M; Wojnar J
Przegl Lek; 2016; 73(1):46-8. PubMed ID: 27120948
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).
Kizub DA; Miao J; Schubert MM; Paterson AHG; Clemons M; Dees EC; Ingle JN; Falkson CI; Barlow WE; Hortobagyi GN; Gralow JR
Support Care Cancer; 2021 May; 29(5):2509-2517. PubMed ID: 32929540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
